Progress of research on glucose transporter proteins in hepatocellular carcinoma  

作　　者：Zheng Ruan Yan Wang Lei Shi Xiao-Jun Yang 

机构地区：[1]The First Clinical Medical School,Gansu University of Chinese Medicine,Lanzhou 730000,Gansu Province,China [2]Division of Personnel,Gansu Provincial People’s Hospital,Lanzhou 730000,Gansu Province,China [3]Department of General Surgery,The Second people’s Hospital of Lanzhou,Lanzhou 730000,Gansu Province,China [4]Department of General Surgery,Gansu Provincial People’s Hospital,Lanzhou 730000,Gansu Province,China

出　　处：《World Journal of Hepatology》2025年第3期77-89,共13页世界肝病学杂志(英文)

摘　　要：Hepatocellular carcinoma(HCC)is a malignant tumour with high prevalence and mortality rate worldwide.Metabolic reprogramming of cancer cells may be a major factor in the process of this disease.Glucose transporter proteins(GLUTs)are members of the major facilitator superfamily of membrane transporters,playing a pivotal role in the metabolic reprogramming and tumour progression in HCC.This review discusses the advances in the study of GLUTs in HCC,in-cluding the expression patterns,functions and possibilities of GLUTs.In HCC,the expression levels of GLUTs are closely associated with tumour aggressiveness,metabolic reprogramming and prognosis.A series of inhibitors have been de-monstrated efficacy in inhibiting HCC cell growth and glucose uptake in in vitro and in vivo models.These inhibitors offer a novel approach to HCC treatment by reducing the glucose metabolism of tumour cells,thereby impeding tumour growth,and concurrently enhancing the sensitivity to chemotherapeutic agents.This reminds us of the urgent need to elucidate GLUTs’roles in HCC and to determine the most effective ways to translate these findings into clinical practice.

关 键 词：Hepatocellular carcinoma Glucose transporter protein Metabolic repro-gramming Therapeutic target Drug resistance 

分 类 号：R73[医药卫生—肿瘤]